The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of ...

In hepatitis B (HBV), Gilead will present initial results from a Phase 1a study of a novel investigational therapeutic vaccine that shows early promise towards the goal of achieving a functional ...

Dr. Makeda Dawkins discusses liver disease risks for African Americans, debunks detox myths, and shares prevention strategies ...

Last week the annual World Hepatitis Day was held, and campaigners have called on all strains of viral hepatitis – dominated by hep C and hep B - to be ... stage or other markers, extending ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients ...

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.

The laboratory findings showed elevated inflammatory markers, lymphopenia ... identified as the aetiology of EN and mainly includes infectious mononucleosis, hepatitis B and C, HIV, herpes simplex ...

There's a vaccine for hepatitis B that, according to the CDC, can help to prevent millions of deaths worldwide.

Dynavax is kicking off May’s Hepatitis Awareness Month with a new push to improve education around hepatitis B and the ...

A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...